Long-Acting Muscarinic Antagonist (LAMA)

Self-Administered - oral inhalation

Step Therapy (ST)

Diagnosis considered for coverage:
  • Tudorza Pressair
    • Chronic obstructive pulmonary disease (COPD) - Indicated for the long-term, maintenance treatment of bronchospasm associated with COPD.
  • Seebri Neohaler
    • COPD - Indicated for the long-term, maintenance treatment of airflow obstruction in patients with COPD.
  • Incruse Ellipta
    • COPD - Indicated for the maintenance treatment of patients with COPD.
Coverage Criteria:

Request for Tudorza Pressair, Seebri Neohaler, or Incruse Ellipta for the treatment of COPD:

  • Dose does not exceed the maximum approved by the Food and Drug Administration (FDA); AND
    • Tudorza Pressair - 400 mcg (1 oral inhalation) twice daily.
    • Seebri Neohaler - 15.6 mcg (1 oral inhalation) twice daily.
    • Incruse Ellipta - 62.5 mcg (1 inhalation) once daily.
  • Patient has tried and failed, contraindication, or intolerable side effects to Spiriva Handihaler or Spiriva Respimat.
Coverage Duration:
  • Initial and reauthorizations: 12 months.
Authorization is not covered for the following:

The use of this drug for indications not listed in this policy does not meet the coverage criteria established by the Western Health Advantage (WHA) Pharmacy and Therapeutics (P&T) Committee.

Additional Information:
  • Preferred agents are Spriva Handihaler and Spiriva Respimat.
  • LAMA medications are not rescue medicines and should not be used for treating sudden breathing problems.
  • Seebri Neohaler was discontinued and removed from the market by the manufacturer in April 2020.
Policy Updates:
  • 06/15/2021 – Utilization management of Tudorza Pressair, Seebri Neohaler, and Incruse Ellipta converted to step therapy with single step edit. Incruse Ellipta formulary status changed from preferred brand (PB) to non-preferred brand (NPB). Spiriva Respimat formulary status changed from NPB to PB.
References:
  • Tudorza Prescribing Information. AstraZeneca Pharmaceuticals. Wilmington, DE. March 2019.
  • Seebri Neohaler Prescribing Information. Novartis Pharmaceuticals Corporation. East Hanover, NJ. January 2017.
  • Incruse Prescribing Information. GlaxoSmithKline. Research Triangle Park, NC. April 2019.
  • Centers for Disease Control and Prevention. Chronic obstructive pulmonary disease (COPD). https://www.cdc.gov/copd/index.html. Updated June 5, 2018[a]. Accessed January 5, 2019.
  • Dahl R, Kaplan A. A systematic review of comparative studies of tiotropium Respimat and tiotropium Handihaler in patients with chronic obstructive pulmonary disease: does inhaler choice matter? BMC Pulm Med. 2016;16(1):135.
  • Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. http://goldcopd.org/gold-reports/. 2019 Report. Accessed January 5, 2019.
  • Ismaila AS, Huisman EL, Punekar YS, et al. Comparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: a systematic review and network meta-analysis. Int J Chron Obstruct Pulmon Dis. 2015;10:2495-2517.
  • Ni H, Htet A, Moe S. Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev. 2017;6:CD011897.
  • Ni H, Soe Z, Moe S. Aclidinium bromide for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;9:CD010509.
  • Oba Y, Lone NA. Comparative efficacy of long-acting muscarinic antagonists in preventing COPD exacerbations: a network meta-analysis and meta-regression. Ther Adv Respir Dis. 2015;9(1):3-15.
  • Pleasants RA, Wang T, Gao J, et al. Inhaled umeclidinium in COPD patients: a review and meta-analysis. Drugs. 2016;76:343-361.
  • Wise RA, Anzueto A, Cotton D, et al. Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med. 2013;369(16):1491-1501.

Last review date: September 23, 2021

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone